Project Grant R21AR085716
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$361K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,657,392 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Pittsburgh. The grant funds research to repurpose FDA-approved drugs for the treatment of osteoarthritis (OA) using high-throughput screening in microphysiological models. The project aims to define the capacity of FDA-approved drugs to reverse cartilage-driven and inflammation-driven OA...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $618,629 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado to establish a new "microphysiological joint-on-chip" system. The objective is to create a realistic human joint model that can support mechanistic study of arthritic diseases and rapid testing of candidate treatments. The researchers plan to develop...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,066,302 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Massachusetts Medical School. The grant, effective April 1, 2025 through March 31, 2029, will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), a rich 16-year observational study with comprehensive...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to identify peptides that preferentially localize to osteoarthritic (OA) joints after intravenous injection and leverage these peptides to develop targeted OA drug carriers. The $208,627 award, granted on Jul 11, 2024, will fund research activities at the University of Florida and the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research into the molecular regulatory mechanisms of a cartilage-enriched G protein-coupled receptor (GPCR) named ADGRG6 in maintaining joint homeostasis and preventing osteoarthritis (OA). The $426,889 award, effective from April 10, 2025 to March 31, 2030, will enable the University...
This $578,944 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The primary objective is to decipher the genetics of osteoarthritis (OA) susceptibility, heterogeneity, and progression. The research aims to identify new and fine-map known genetic loci associated with OA and total joint replacement, disentangle OA heterogeneity by...
This Project Grant award of $404,187 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to explore the role of the Notch2 signaling pathway in the development of osteoarthritis and associated inflammatory responses. The University of Connecticut Health Center will conduct this research over a period of 5 years, with a goal of establishing the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding research to investigate the mechanistic links between gait biomechanics and the development of knee osteoarthritis (KOA). The $644,152 award, which runs from January 2025 to December 2029, will be used by the University of North Carolina at Chapel Hill to: 1) determine the acute in vivo...